Response to direct‐acting antivirals for hepatitis C treatment in vertically HIV/HCV co‐infected patients

Direct‐acting antivirals (DAAs) for HCV treatment have improved tolerance and efficacy among adults, but experience in vertical transmission is scarce. In our vertically HIV/HCV co‐infected youth cohort of 58 patients, DAA achieved excellent rates of cure among naïve and pretreated individuals. Trea...

Full description

Saved in:
Bibliographic Details
Published inJournal of viral hepatitis Vol. 27; no. 9; pp. 955 - 958
Main Authors Carrasco, Itzíar, Sainz, Talía, Frick, Marie Antoinette, Jiménez de Ory, Santiago, Fortuny, Claudia, Burgos, Joaquin, Montero, Marta, Gavilán, César, Falcón, María Dolores, Couceiro, José Antonio, Bernardino, José Ignacio, Bisbal, Otilia, Guerrero, Carmelo, Aldámiz‐Echevarría, María Teresa, Berenguer, Juan, Navarro, María Luisa
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.09.2020
Subjects
Antiviral agents
children and adolescents
direct‐acting antivirals
Fibrosis
HCV treatment
Hepatitis C
HIV
Human immunodeficiency virus
vertical transmission
VIH/VHC co‐infection
HCV treatment
children and adolescents
vertical transmission
direct-acting antivirals
VIH/VHC co-infection
Online AccessGet full text

Cover

More Information
Summary:Direct‐acting antivirals (DAAs) for HCV treatment have improved tolerance and efficacy among adults, but experience in vertical transmission is scarce. In our vertically HIV/HCV co‐infected youth cohort of 58 patients, DAA achieved excellent rates of cure among naïve and pretreated individuals. Treating vertically infected seems important as 29.6% displayed advanced fibrosis at treatment initiation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.13308